<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03966638</url>
  </required_header>
  <id_info>
    <org_study_id>CRC_GHN_2019_006</org_study_id>
    <nct_id>NCT03966638</nct_id>
  </id_info>
  <brief_title>Clinical and Radiological Evaluation of Meniscal Healing After Percutaneous Intra-meniscal Injection of Platelet-rich Plasma (PRP)</brief_title>
  <acronym>COMPARE</acronym>
  <official_title>Clinical and Radiological Evaluation of Meniscal Healing After Percutaneous Intra-meniscal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Meniscal lesions are a common pathology among athletes, and have an impact on the daily or
      sporting practice of patients. The consequences of surgical treatment are sometimes heavy.

      Platelet-rich-plasma (PRP) has been shown to be effective in healing tendon and ligament
      lesions.

      PRP has been injected under ultrasound in tendons or intra-articularly for several years.

      This technique of meniscal percutaneous injection of PRP is now carried out for more than 2
      years in our hospital, with satisfactory preliminary results, without any complication.

      All patients in our study received an intra-meniscal injection of PRP, under echographic
      control. They were evaluated clinically and by Magnetic Resonance Imaging (MRI) before and at
      6 months of the injection.

      The aim of the study is to evaluate the efficacy of intra-meniscal injection of PRP on the
      symptomatology of the patients (pain, sport activities and daily life) at 6 months
      post-treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of International Knee Documentation Committee (IKDC) score</measure>
    <time_frame>Between 0 and 6 months post injection</time_frame>
    <description>The variation of IKDC score between before injection and 6 months post-injection will be calculated. The IKDC score ranges from 0 to 100 and is interpreted as a measure of function with higher scores representing higher levels of function.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Meniscus Lesion</condition>
  <arm_group>
    <arm_group_label>Patients receiving platelet rich plasma</arm_group_label>
    <description>The group is composed of patients receiving an intra-meniscal injection of platelet-rich plasma, under echographic control, for isolated meniscal lesion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intra-meniscal injection of platelet-rich plasma</intervention_name>
    <description>Intra-meniscal injection of platelet-rich plasma under echographic control</description>
    <arm_group_label>Patients receiving platelet rich plasma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with symptomatic non-surgical meniscal injury treated with percutaneous intravenous
        injection of platelet-rich plasma (PRP)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  isolated symptomatic meniscal lesion

          -  lesion confirmed by MRI

          -  grade II or III lesion touching the peripheral involvement of the middle segment,

          -  lesion treated by percutaneous intra meniscal PRP's injection

          -  IKDC score measured before injection and 6 months post-injection

        Exclusion Criteria:

          -  other painful etiology of the knee

          -  emergency surgical management (luxation, bucket handle) or not (indication validated
             by the surgeon, meniscectomy or meniscal suture)

          -  impossibility to perform the procedure (non visible lesion, morphology of the patient,
             cutaneous infection, coagulation treatment in progress)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>hadrien Neyra, MD</last_name>
    <phone>+33-4 26109181</phone>
    <email>hadrien.neyra@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabien Craighero, MD</last_name>
    <phone>+33-4 26 10 91 81</phone>
    <email>fabien.craighero@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiology, Croix-Rousse Hospital, Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hadrien Neyra, MD</last_name>
      <phone>+33-426 10 91 81</phone>
      <email>hadrien.neyra@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Fabien Craighero, MD</last_name>
      <phone>+33-426 10 91 81</phone>
      <email>fabien.craighero@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

